SPRYD4

Across TCGA pan-cancer cohorts, SPRYD4 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SPRYD4’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where SPRYD4 RNA is repressed in tumor relative to normal tissue. In most cancer types SPRYD4 is over-expressed in tumor, although a few such as KICH and LIHC show the opposite, repressed pattern.

KICH, LIHC, and THCA are the cancer types where SPRYD4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPRYD4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Male	III,IV	−1.507	<.001	11	view →
LIHC	Male	II,III,IV	−0.907	<.001	8	view →
THCA	Male	IV	−0.706	.001	8	view →
LUSC	Female	All	+0.669	<.001	8	view →
KIRC	Male	III,IV	−0.501	<.001	8	view →
KIRP	Male	All	−0.388	.003	7	view →
CHOL	Male	All	−1.240	<.001	3	view →
LUAD	Female	All	+0.291	<.001	3	view →
STAD	All	II,III,IV	+0.324	.012	2	view →
PRAD	All	All	+0.324	<.001	2	view →
BLCA	Female	III,IV	+0.529	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SPRYD4–KICH

Open the KICH breakdown →